Home › Companies › TG Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and TG Therapeutics, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore TG Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are TG Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Michael S. Weiss | 72,172,630 | -- | -- | 9,260,279 | 31,570,505 | Majority: yes |
| Elect Director: Laurence N. Charney | 68,135,448 | -- | -- | 13,297,461 | 31,570,505 | Majority: yes |
| Elect Director: Yann Echelard | 64,110,661 | -- | -- | 17,322,248 | 31,570,505 | Majority: yes |
| Elect Director: Kenneth Hoberman | 53,354,717 | -- | -- | 28,078,192 | 31,570,505 | Majority: yes |
| Elect Director: Daniel Hume | 63,979,535 | -- | -- | 17,453,374 | 31,570,505 | Majority: yes |
| Elect Director: Sagar Lonial, MD | 44,666,544 | -- | -- | 36,766,365 | 31,570,505 | Majority: yes |
| Proposal 2 The vote with respect to the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: | 112,329,330 | 531,758 | 142,326 | -- | -- | Majority: yes |
| Proposal 3 The advisory vote to approve the compensation of the Company's named executive officers was as follows: | 31,905,837 | 48,858,169 | 668,903 | -- | 31,570,505 | Majority: no |
Source: TG Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.
Each item below shows how the 360 asset managers that disclosed a TG Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of TG Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
40% Majority: no · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Proposal 3 The advisory vote to approve the compensation of the Company's named executive officers was as follows:”): 31,905,837 for, 48,858,169 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 21% for, 32% against (52.8% of the company cast a for/against vote).
The 358 asset managers below cast 25% of the shares they voted on this item FOR (19,035,795 for, 56,503,174 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,659,044 | 10,227,156 | 6 | 0 | Against |
| BlackRock | 9,440 | 11,695,462 | 0 | 0 | Against |
| State Street | 13,921 | 5,818,662 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 0 | 3,127,235 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 2,564,065 | 0 | 0 | Against |
| Charles Schwab | 0 | 2,439,835 | 0 | 0 | Against |
| Fidelity | 0 | 2,432,672 | 0 | 0 | Against |
| CONGRESS ASSET MANAGEMENT CO | 2,322,397 | 14,750 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 1,610,023 | 0 | 0 | Against |
| Nuveen | 1,568,743 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 1,523,579 | 0 | 0 | Against |
| TIAA | 1,521,720 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 1,500,390 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,110,006 | 0 | 0 | Against |
| Northern Trust | 0 | 1,050,412 | 0 | 0 | Against |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| Goldman Sachs | 737,280 | 11,614 | 0 | 0 | For |
| Voya | 0 | 720,240 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 0 | 664,762 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 650,840 | 0 | 0 | Against |
| Invesco | 0 | 561,337 | 0 | 0 | Against |
| Two Sigma | 0 | 520,226 | 0 | 0 | Against |
| BANK OF MONTREAL /CAN/ | 0 | 504,593 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 363,204 | 0 | 0 | Against |
Showing the 25 largest of 358 asset managers. See all 358 in the interactive database.
Combines 7 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Daniel Hume”): 63,979,535 for, 17,453,374 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 42% for, 11% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (32,405,877 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,273,516 | 0 | 1,399,185 | 0 | For |
| BlackRock | 7,168,562 | 0 | 0 | 0 | For |
| State Street | 3,632,447 | 0 | 4,697 | 0 | For |
| Fidelity | 2,223,353 | 0 | 99,191 | 0 | For |
| Legg Mason | 0 | 0 | 1,523,579 | 0 | Abstain |
| TIAA | 0 | 0 | 1,521,720 | 0 | Abstain |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,138,044 | 0 | Abstain |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 206,273 | 0 | 154,570 | 0 | For |
| Jackson National | 0 | 0 | 307,351 | 0 | Abstain |
| Voya | 301,568 | 0 | 0 | 0 | For |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 235,816 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 207,096 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 96,000 | 0 | 60,745 | 0 | For |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 120,181 | 0 | Abstain |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 7 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Kenneth Hoberman”): 53,354,717 for, 28,078,192 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 35% for, 18% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (26,641,075 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,576,805 | 0 | 95,896 | 0 | For |
| BlackRock | 301,375 | 0 | 6,867,187 | 0 | Abstain |
| State Street | 3,632,447 | 0 | 4,697 | 0 | For |
| Fidelity | 6,601 | 0 | 2,315,943 | 0 | Abstain |
| Legg Mason | 1,510,647 | 0 | 12,932 | 0 | For |
| TIAA | 1,521,720 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,138,044 | 0 | Abstain |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 38,000 | 0 | 322,843 | 0 | Abstain |
| Jackson National | 0 | 0 | 307,351 | 0 | Abstain |
| Voya | 0 | 0 | 301,568 | 0 | Abstain |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 235,816 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 207,096 | 0 | Abstain |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 96,000 | 0 | 60,745 | 0 | For |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 120,181 | 0 | Abstain |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 8 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Laurence N. Charney”): 68,135,448 for, 13,297,461 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 45% for, 9% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (36,779,568 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,576,840 | 0 | 95,861 | 0 | For |
| BlackRock | 7,168,562 | 0 | 0 | 0 | For |
| State Street | 3,632,447 | 0 | 4,697 | 0 | For |
| Fidelity | 2,223,353 | 0 | 99,191 | 0 | For |
| Legg Mason | 1,510,647 | 0 | 12,932 | 0 | For |
| TIAA | 1,521,720 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,138,044 | 0 | Abstain |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 244,273 | 0 | 116,570 | 0 | For |
| Jackson National | 0 | 0 | 307,351 | 0 | Abstain |
| Voya | 301,568 | 0 | 0 | 0 | For |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 235,816 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 207,096 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 96,000 | 0 | 60,745 | 0 | For |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 120,181 | 0 | Abstain |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael S. Weiss”): 72,172,630 for, 9,260,279 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 47.1% for, 6% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (38,704,872 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,537,524 | 0 | 135,177 | 0 | For |
| BlackRock | 7,168,562 | 0 | 0 | 0 | For |
| State Street | 3,627,392 | 0 | 9,752 | 0 | For |
| Fidelity | 2,314,244 | 0 | 8,300 | 0 | For |
| Legg Mason | 1,510,647 | 0 | 12,932 | 0 | For |
| TIAA | 1,521,720 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,138,044 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 244,273 | 0 | 116,570 | 0 | For |
| Jackson National | 281,864 | 0 | 25,487 | 0 | For |
| Voya | 301,568 | 0 | 0 | 0 | For |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 235,816 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 207,096 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 96,000 | 0 | 60,745 | 0 | For |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 120,181 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 8 wordings of this item as funds reported it.
54.9% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Sagar Lonial, MD”): 44,666,544 for, 36,766,365 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 29% for, 24% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (20,309,708 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,273,421 | 0 | 1,399,280 | 0 | For |
| BlackRock | 0 | 0 | 7,168,562 | 0 | Abstain |
| State Street | 8,330 | 0 | 3,628,814 | 0 | Abstain |
| Fidelity | 2,148,402 | 0 | 174,142 | 0 | For |
| Legg Mason | 0 | 0 | 1,523,579 | 0 | Abstain |
| TIAA | 0 | 0 | 1,521,720 | 0 | Abstain |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,138,044 | 0 | Abstain |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 0 | 0 | 360,843 | 0 | Abstain |
| Jackson National | 0 | 0 | 307,351 | 0 | Abstain |
| Voya | 0 | 0 | 301,568 | 0 | Abstain |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 235,816 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 207,096 | 0 | Abstain |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 156,745 | 0 | Abstain |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 120,181 | 0 | Abstain |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 7 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Elect Director: Yann Echelard”): 64,110,661 for, 17,322,248 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 42% for, 11% withheld (53.2% of the company cast a for/withheld vote).
The 89 asset managers below cast 100% of the shares they voted on this item FOR (32,405,878 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,273,517 | 0 | 1,399,184 | 0 | For |
| BlackRock | 7,168,562 | 0 | 0 | 0 | For |
| State Street | 3,632,447 | 0 | 4,697 | 0 | For |
| Fidelity | 2,223,353 | 0 | 99,191 | 0 | For |
| Legg Mason | 0 | 0 | 1,523,579 | 0 | Abstain |
| TIAA | 0 | 0 | 1,521,720 | 0 | Abstain |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,138,044 | 0 | Abstain |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 410,690 | 0 | Abstain |
| Equitable | 206,273 | 0 | 154,570 | 0 | For |
| Jackson National | 0 | 0 | 307,351 | 0 | Abstain |
| Voya | 301,568 | 0 | 0 | 0 | For |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 235,816 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 207,096 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 174,957 | 0 | Abstain |
| Lincoln Financial | 96,000 | 0 | 60,745 | 0 | For |
| First Trust | 0 | 0 | 146,209 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 131,112 | 0 | Abstain |
| Brighthouse | 0 | 0 | 128,449 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 120,181 | 0 | Abstain |
| Principal | 0 | 0 | 117,626 | 0 | Abstain |
| ProShares | 0 | 0 | 97,149 | 0 | Abstain |
| Empower | 0 | 0 | 97,034 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Proposal 2 The vote with respect to the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:”): 112,329,330 for, 531,758 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 73% for, 0.4% against (74% of the company cast a for/against vote).
The 89 asset managers below cast 99.8% of the shares they voted on this item FOR (41,036,537 for, 56,542 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,672,695 | 6 | 0 | 0 | For |
| BlackRock | 7,168,562 | 0 | 0 | 0 | For |
| State Street | 3,637,144 | 0 | 0 | 0 | For |
| Fidelity | 2,322,544 | 0 | 0 | 0 | For |
| Legg Mason | 1,523,579 | 0 | 0 | 0 | For |
| TIAA | 1,521,720 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 1,300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,138,044 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 972,563 | 0 | 0 | 0 | For |
| T. Rowe Price | 410,690 | 0 | 0 | 0 | For |
| Equitable | 360,843 | 0 | 0 | 0 | For |
| Jackson National | 307,351 | 0 | 0 | 0 | For |
| Voya | 301,568 | 0 | 0 | 0 | For |
| Goldman Sachs | 278,199 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 235,816 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 207,096 | 0 | 0 | 0 | For |
| Dimensional | 174,957 | 0 | 0 | 0 | For |
| Lincoln Financial | 156,745 | 0 | 0 | 0 | For |
| First Trust | 146,209 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 131,112 | 0 | 0 | 0 | For |
| Brighthouse | 99,271 | 0 | 29,178 | 0 | For |
| BNY Mellon | 120,181 | 0 | 0 | 0 | For |
| Principal | 117,626 | 0 | 0 | 0 | For |
| ProShares | 97,149 | 0 | 0 | 0 | For |
| Empower | 97,034 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.
99.5% Majority: yes · of votes cast
TG Therapeutics, Inc.’s own tally for this item (“Proposal 2 The vote with respect to the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:”): 112,329,330 for, 531,758 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 153,083,580 outstanding shares: 73% for, 0.4% against (74% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (34,923 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TEALWOOD ASSET MANAGEMENT INC | 21,223 | 0 | 0 | 0 | For |
| AMERICAN PENSION INVESTORS TRUST | 13,700 | 0 | 0 | 0 | For |
Ranked by the number of TG Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 153,083,580 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.68% |
| 2 | BlackRock | 7.65% |
| 3 | State Street | 3.81% |
| 4 | Clearbridge Investments, LLC | 2.04% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.67% |
| 6 | Charles Schwab | 1.59% |
| 7 | Fidelity | 1.59% |
| 8 | CONGRESS ASSET MANAGEMENT CO | 1.53% |
| 9 | PICTET ASSET MANAGEMENT SA | 1.05% |
| 10 | Nuveen | 1.02% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 14.54% | 13F |
| Vanguard Group | 10.35% | 13F |
| State Street | 5.65% | 13F |
| Geode Capital | 2.29% | 13F |
| Goldman Sachs | 2.01% | 13F |
| Citadel Advisors | 1.60% | 13F |
| Two Sigma | 1.01% | 13F |
| Morgan Stanley | 0.98% | 13F |
| Northern Trust | 0.94% | 13F |
| Charles Schwab | 0.85% | 13F |
Percentages above are of 153,083,580 shares outstanding, as reported by TG Therapeutics, Inc. on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TG Therapeutics, Inc.’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At TG Therapeutics, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 360 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,998 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — An advisory vote to approve the compensation of our named executive officers. — FOR was 40% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: TG Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.
TG Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).